A role for the B-cell CD74/macrophage migration inhibitory factor pathway in the immunomodulation of systemic lupus erythematosus by a therapeutic tolerogenic peptide

Immunology

Volumn 132, Issue 1, 2011, Pages 87-95

  Lapter, Smadar ^a   Ben David, Hava ^a   Sharabi, Amir ^a   Zinger, Heidy ^a   Telerman, Alona ^a   Gordin, Maya ^a   Leng, Lin ^b   Bucala, Richard ^b   Shachar, Idit ^a   Mozes, Edna ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; B cells; Lupus systemic lupus erythematosus; Peptide immunotherapy; Signalling

Indexed keywords

CD74 ANTIGEN; GLYCYLTYROSYLTYROSYLTRYPTOPHYLSERYLTRYPTOPHYLISOLEUCYLARGINYLGLUTAMINYLPROLYLPROLYLGLYCYLLYSYLGLYCYLGLUTAMYLGLUTAMYLTRYPTOPHYLISOLEUCYLGLYCINE; HERMES ANTIGEN; IMMUNOMODULATING AGENT; MACROPHAGE MIGRATION INHIBITION FACTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL SURVIVAL; COMPLEMENTARITY DETERMINING REGION; DOWN REGULATION; FEMALE; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; UPREGULATION;

ANIMALS; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; APOPTOSIS; AUTOANTIGENS; B-LYMPHOCYTES; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOMODULATION; INTRAMOLECULAR OXIDOREDUCTASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MICE; MICE, INBRED NZB; NERVE TISSUE PROTEINS; PEPTIDES;

EID: 78650011822     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2010.03342.x     Document Type: Article

References (51)

1. Hahn BH. An overview of the pathogenesis of systemic lupus erythematosus. In: Wallace DJ, Hahn BH, eds. Dubois' lupus erythematosus. Philadelphia, PA: Lippincott Williams & Wilkins, 2006:46-53.
2. Sthoeger ZM, Dayan M, Tcherniack A, Green L, Toledo S, Segal R, Elkayam O, Mozes E. Modulation of autoreactive responses of peripheral blood lymphocytes of patients with systemic lupus erythematosus by peptides based on human and murine anti-DNA autoantibodies. Clin Exp Immunol 2003; 131:385-92.
3. Waisman A, Shoenfeld Y, Blank M, Ruiz PJ, Mozes E. The pathogenic human monoclonal anti-DNA that induces experimental systemic lupus erythematosus in mice is encoded by a VH4 gene segment. Int Immunol 1995; 7:689-96.
4. Luger D, Dayan M, Zinger H, Liu JP, Mozes E. A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation. J Clin Immunol 2004; 24:579-90.
5. Lapter S, Marom A, Meshorer A et al. Amelioration of brain pathology and behavioral dysfunction in mice with lupus following treatment with a tolerogenic peptide. Arthritis Rheum 2009; 60:3744-54.
6. + cells and TGF-β. Proc Natl Acad Sci USA 2006; 103:8810-5.
7. Sharabi A, Mozes E. The suppression of murine lupus by a tolerogenic peptide involves foxp3-expressing CD8 cells that are required for the optimal induction and function of foxp3-expressing CD4 cells. J Immunol 2008; 181:3243-51.
8. Sharabi A, Luger D, Ben-David H, Dayan M, Zinger H, Mozes E. The role of apoptosis in the ameliorating effects of a CDR1-based peptide on lupus manifestations in a mouse model. J Immunol 2007; 179:4979-87.
9. Sharabi A, Lapter S, Mozes E. Bcl-xL is required for the development of functional regulatory CD4 cells in lupus-afflicted mice following treatment with a tolerogenic peptide. J Autoimmun 2010; 34:87-95.
10. Sela U, Dayan M, Hershkoviz R, Cahalon L, Lider O, Mozes E. The negative regulators Foxj1 and Foxo3a are up-regulated by a peptide that inhibits systemic lupus erythematosus-associated T cell responses. Eur J Immunol 2006; 36:2971-80.
11. Sela U, Dayan M, Hershkoviz R, Lider O, Mozes E. A peptide that ameliorates lupus up-regulates the diminished expression of early growth response factors 2 and 3. J Immunol 2008; 180:1584-91.
12. Grammer AC, Lipsky PE. B cell abnormalities in systemic lupus erythematosus. Arthritis Res Ther 2003; 5(Suppl. 4):S22-7.
13. Crowley JE, Treml LS, Stadanlick JE, Carpenter E, Cancro MP. Homeostatic niche specification among naive and activated B cells: a growing role for the BLyS family of receptors and ligands. Semin Immunol 2005; 17:193-9.
14. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001; 44:1313-9.
15. Gross JA, Johnston J, Mudri S et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000; 404:995-9.
16. Parameswaran R, Ben David H, Sharabi A, Zinger H, Mozes E. B-cell activating factor (BAFF) plays a role in the mechanism of action of a tolerogenic peptide that ameliorates lupus. Clin Immunol 2009; 131:223-32.
17. Starlets D, Gore Y, Binsky I et al. Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival. Blood 2006; 107:4807-16.
18. Sapoznikov A, Pewzner-Jung Y, Kalchenko V, Krauthgamer R, Shachar I, Jung S. Perivascular clusters of dendritic cells provide critical survival signals to B cells in bone marrow niches. Nat Immunol 2008; 9:388-95.
19. Gore Y, Starlets D, Maharshak N, Becker-Herman S, Kaneyuki U, Leng L, Bucala R, Shachar I. Macrophage migration inhibitory factor induces B cell survival by activation of a CD74-CD44 receptor complex. J Biol Chem 2008; 283:2784-92.
20. Stumptner-Cuvelette P, Benaroch P. Multiple roles of the invariant chain in MHC class II function. Biochim Biophys Acta 2002; 1542:1-13.
21. Naujokas MF, Morin M, Anderson MS, Peterson M, Miller J. The chondroitin sulfate form of invariant chain can enhance stimulation of T cell responses through interaction with CD44. Cell 1993; 74:257-68.
22. Shi X, Leng L, Wang T et al. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 2006; 25:595-606.
23. Leng L, Metz CN, Fang Y et al. MIF signal transduction initiated by binding to CD74. J Exp Med 2003; 197:1467-76.
24. Shachar I, Flavell RA. Requirement for invariant chain in B cell maturation and function. Science 1996; 274:106-8.
25. Matza D, Lantner F, Bogoch Y, Flaishon L, Hershkoviz R, Shachar I. Invariant chain induces B cell maturation in a process that is independent of its chaperonic activity. Proc Natl Acad Sci USA 2002; 99:3018-23.
26. Matza D, Kerem A, Shachar I. Invariant chain, a chain of command. Trends Immunol 2003; 24:264-8.
27. Hoi AY, Hickey MJ, Hall P et al. Macrophage migration inhibitory factor deficiency attenuates macrophage recruitment, glomerulonephritis, and lethality in MRL/lpr mice. J Immunol 2006; 177:5687-96.
28. Foote A, Briganti EM, Kipen Y, Santos L, Leech M, Morand EF. Macrophage migration inhibitory factor in systemic lupus erythematosus. J Rheumatol 2004; 31:268-73.
29. Bernhagen J, Mitchell RA, Calandra T, Voelter W, Cerami A, Bucala R. Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry 1994; 33:14144-55.
30. Groom J, Mackay F. B cells flying solo. Immunol Cell Biol 2008; 86:40-6.
31. Mauermann N, Sthoeger Z, Zinger H, Mozes E. Amelioration of lupus manifestations by a peptide based on the complementarity determining region 1 of an autoantibody in severe combined immunodeficient (SCID) mice engrafted with peripheral blood lymphocytes of systemic lupus erythematosus (SLE) patients. Clin Exp Immunol 2004; 137:513-20.
32. Sharabi A, Haviv A, Zinger H, Dayan M, Mozes E. Amelioration of murine lupus by a peptide, based on the complementarity determining region-1 of an autoantibody as compared to dexamethasone: different effects on cytokines and apoptosis. Clin Immunol 2006; 119:146-55.
33. Sharabi A, Azulai H, Sthoeger ZM, Mozes E. Clinical amelioration of murine lupus by a peptide based on the complementarity determining region-1 of an autoantibody and by cyclophosphamide: similarities and differences in the mechanisms of action. Immunology 2007; 121:248-57.
34. Mitchell RA, Metz CN, Peng T, Bucala R. Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). regulatory role in cell proliferation and glucocorticoid action. J Biol Chem 1999; 274:18100-6.
35. Damico RL, Chesley A, Johnston L et al. Macrophage migration inhibitory factor governs endothelial cell sensitivity to LPS-induced apoptosis. Am J Respir Cell Mol Biol 2008; 39:77-85.
36. Binsky I, Haran M, Starlets D et al. IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. Proc Natl Acad Sci USA 2007; 104:13408-13.
37. Enzler T, Bonizzi G, Silverman GJ, Otero DC, Widhopf GF, Anzelon-Mills A, Rickert RC, Karin M. Alternative and classical NF-κB signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. Immunity 2006; 25:403-15.
38. Hahn BH. Antibodies to DNA. N Engl J Med 1998; 338:1359-68.
39. Waldman M, Madaio MP. Pathogenic autoantibodies in lupus nephritis. Lupus 2005; 14:19-24.
40. Ma X, Foster J, Sakic B. Distribution and prevalence of leukocyte phenotypes in brains of lupus-prone mice. J Neuroimmunol 2006; 179:26-36.
41. Zandman-Goddard G, Chapman J, Shoenfeld Y. Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. Semin Arthritis Rheum 2007; 36:297-315.
42. Tin SK, Xu Q, Thumboo J, Lee LY, Tse C, Fong KY. Novel brain reactive autoantibodies: prevalence in systemic lupus erythematosus and association with psychoses and seizures. J Neuroimmunol 2005; 169:153-60.
43. Scolding NJ, Joseph FG. The neuropathology and pathogenesis of systemic lupus erythematosus. Neuropathol Appl Neurobiol 2002; 28:173-89.
44. Lan HY, Yang N, Nikolic-Paterson DJ et al. Expression of macrophage migration inhibitory factor in human glomerulonephritis. Kidney Int 2000; 57:499-509.
45. Vera PL, Wang X, Meyer-Siegler KL. Upregulation of macrophage migration inhibitory factor (MIF) and CD74, receptor for MIF, in rat bladder during persistent cyclophosphamide-induced inflammation. Exp Biol Med 2008; 233:620-6.
46. Kirimca F, Sarioglu S, Camsari T, Kavukcu S. Expression of CD44 and major histocompatibility complex class II antigens correlate with renal scarring in primary and systemic renal diseases. Scand J Urol Nephrol 2001; 35:509-14.
47. Yoshiyama Y, Arai K, Oki T, Hattori T. Expression of invariant chain and pro-cathepsin L in Alzheimer's brain. Neurosci Lett 2000; 290:125-8.
48. Bryan KJ, Zhu X, Harris PL, Perry G, Castellani RJ, Smith MA, Casadesus G. Expression of CD74 is increased in neurofibrillary tangles in Alzheimer's disease. Mol Neurodegener 2008; 3:13.
49. Li Y, Harada T, Juang YT, Kyttaris VC, Wang Y, Zidanic M, Tung K, Tsokos GC. Phosphorylated ERM is responsible for increased T cell polarization, adhesion, and migration in patients with systemic lupus erythematosus. J Immunol 2007; 178:1938-47.
50. Crispin JC, Keenan BT, Finnell MD et al. Expression of CD44 variant isoforms CD44v3 and CD44v6 is increased on T cells from patients with systemic lupus erythematosus and is correlated with disease activity. Arthritis Rheum 2010; 62:1431-7.
51. Sela U, Mauermann N, Hershkoviz R et al. The inhibition of autoreactive T cell functions by a peptide based on the CDR1 of an anti-DNA autoantibody is via TGF-beta-mediated suppression of LFA-1 and CD44 expression and function. J Immunol 2005; 175:7255-63.